What's Hot
View all perspectives
Aurelie Najm
1 year ago
VROOM 🏎️ study
2 wks interruption of MTX just after COVID vaccine:
-Increase S1-RBD Ab response for 26 wks
-Improves Neutralizing Ab titres (Wuhan Hu-1)
-Leads to more flares wks 4 & 12
Greater effect when MTX dose>15mg
@RheumNow #ACR23 ABST1677 https://t.co/SJmaRHtbRH
Richard Conway
1 year ago
Abishek et al. 2 week break from MTX enhances response to COVID-19 vaccination, mirroring what we saw for flu. Trade off is short term worsening of disease activity. Abstr#1677 #ACR23 @RheumNow https://t.co/gguRWER81x https://t.co/1hncvDTahH
Dr. Antoni Chan
1 year ago
There was a lower hazard ratio for incident cancer with exposure to TNFi compared to non-TNFi (RTX and ABA) and JAKi. Limits: potential for residual confounding by indication and small number of outcomes per drug class, Xavier S, Abst#1678 #ACR23 @RheumNow https://t.co/vJpFwl6Ivj
Eric Dein
1 year ago
A#1403 #ACR23 @RheumNow
17% of 1st degree relatives of AS pts have MRI-defined sacroiliitis
Study of 100 subjects w FHx AS
- 13/100: new dx of AxSpA, 7 w radiographic changes
- 4/100: Sacroiliitis without back pain
- 1 periph SpA
- 12 met clinical ASAS classification but not dx https://t.co/V7LCbaDXBe
Methotrexate is widely used in rheumatic diseases yet poses common tolerance issues, especially for the oral form; and bioavailability is known to be limited for doses over 15mg. In the SMART study, Prasad et al. present the first RCT comparing either single dose (25 mg) or split-dose (10 mg morning, 15 mg evening, same day) once weekly MTX for 24 weeks.
Dr. John Cush RheumNow
1 year ago
OA and Syncope #ACR23
OA patient on NSAIDs presents with a peptic ulcer and GI Bleed.
https://t.co/vhRnv6dPim https://t.co/H4gsCivyxN
Eric Dein
1 year ago
GCs Major Driver of Depression in SLE Ab#1446 #ACR23
@RheumNow
1463 pts with SLE, prospective longitudinal study GC use: 49-57% of pts Prevalence of depression at any time: 89.8%, most of time 35%!! Risk factors: - Fibromyalgia OR 2.9 - GC OR 1.85
David Liew drdavidliew
1 year ago
Hand movement video: more promising than photos as a computer vision concept for remote monitoring of RA disease activity.
Of course: validation, training, clinical evaluation all must happen before it is ready for your clinic
https://t.co/HyN6ElKF0F #ACR23 ABST1293 @RheumNow https://t.co/DltI9HFiFE
Aurelie Najm
1 year ago
Fatigue 😴 in RA & synovial biology
In DAS LDA pts Fatigue asso w/
-female sex
-synovial lymphocytic inflammation
In DAS moderate DA:
-female sex
-synovial lining layer
-Anxiety
Limitations: arthroplasty tissue, small sample size, no Immunohisto
@RheumNow #ACR23 ABST1630 https://t.co/4vhzvdPgyd
Eric Dein
1 year ago
PRES in SLE
A#1478 @RheumNow #ACR23
303 cases of Posterior Reversible Encephalopathy Syndrome in SLE
- Mean age 28, 91% F
- 42% HTN, HLD 15%, DM 10%
- 83% lupus nephritis. 80% dsDNA, 41% Sm, 38% aPL
- 78% seizures
- 3% mortality
- Transient in 45%, persistent in 19%, 8% sequelae
Md Yuzaiful Md Yusof
1 year ago
#ACR23 Abstr#1636 Phase 2 crossover RCT of Dazodalibep, Anti-CD40L-i in #Sjogren pts with high disease activity showed primary endpoint, change in ESSDAI was met in DAZ vs PBO. More COVID in DAZ in Stage 1 but trial was at the start of pandemic. Phase 3 is starting soon @RheumNow https://t.co/hZcpOHumB3
Poster Hall